Table 1 The demographic and clinical characteristics of the participants
Training Group | Validation Group | |||||
|---|---|---|---|---|---|---|
BC | UD | NC | BC | UD | NC | |
Total No. | 74 | 23 | 51 | 120 | 15 | 45 |
No. gender (%) | ||||||
Female | 7 (9.5) | 8 (34.8) | 15 (29.4) | 21(17.5) | 5(33.3) | 9 (20) |
Male | 67 (90.5) | 15 (65.2) | 36 (70.6) | 99(82.5) | 10(66.7) | 36 (80) |
Median age (range) | 62 (28–90) | 56 (18–72) | 41 (23–69) | 62(33–93) | 54(22–73) | 40(21–66) |
Primary (%) | 61 (82.4) | – | – | 106(88.3) | – | – |
Recurrent (%) | 13 (17.6) | – | – | 14(11.7) | – | – |
No. tumour stage (%) | ||||||
Tis | 1 (1.4) | – | – | 2(1.7) | – | – |
Ta | 23 (31.1) | 34(28.3) | ||||
T1 | 24 (32.4) | 61(50.8) | ||||
T2 | 16 (21.6) | 13(10.8) | ||||
T3 | 5 (6.8) | 10(8.3) | ||||
NA | 5 (6.8) | 0(0.0) | ||||
No. tumour grade (%) | ||||||
PUNLMP | 5(6.8) | – | – | 0(0.0) | – | – |
LG | 9(12.2) | 33(27.5) | ||||
HG | 59 (79.7) | 83(69.2) | ||||
NA | 1 (1.4) | 4(3.3) | ||||